Christopher Riedl, MD, PhD


Memorial Sloan Kettering radiologist Christopher Riedl
LocationA pin, used as a metaphor for the concept of location. Locations Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.
Phone iconAn icon showing a telephone. Phone Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

About Me

I am a diagnostic radiologist and nuclear medicine physician with specialist training in molecular imaging as well as breast and body oncologic imaging. I have more than 15 years of experience in the field. My work has helped standardize care and improve early breast cancer detection rates for people at high risk for breast cancer.

My father was a radiologist, and as a child I thought he was nothing short of a magician. As I grew older, I learned more about the science behind his work and the miraculous machines that allowed him to see inside the human body. It was a career path I was compelled to follow.

My passion for nuclear medicine started during my research fellowship at MSK in 2004. Recent research advances in cancer therapy have led to the development of an ever-increasing number of tailor-made drugs designed to target and kill specific subtypes of cancer. The drugs have high efficacy with few side effects. With molecular imaging, we can try to find the exact drug that is best suited to individual patients; this is personalized medicine at its best. I am honored to work with colleagues who have helped build this fascinating field from the ground up.

Another field that has fascinated me for more than a decade is breast-cancer imaging. As a radiology resident in Vienna, I led a large-scale national trial in Austria that confirmed the superiority of MRI in detecting invasive and preinvasive breast cancers in women with a genetic predisposition for the disease. Results of this study were published in Clinical Cancer Research and Journal of Clinical Oncology. Thanks to this and a few similar studies, many countries changed their guidelines to now recommend MRI breast cancer screening for patients at high risk for breast cancer.

In the decade since, I have continued to do clinical and research work in the areas of nuclear medicine and breast cancer imaging. As the most common cancer in women in the western world, often affecting young patients, breast cancer presents a crucial and fascinating field of study and care. My work is focused on testing and evaluating innovative PET radiopharmaceuticals for cutting-edge breast cancer treatment to help bring these new treatments to our patients.

  • Clinical Expertise: PET/CT; Nuclear Medicine; CT; MRI Ultrasound; X-Ray
  • Languages Spoken: English; German; Spanish
  • Education: PhD, Universidad de la Laguna (Spain); MD, Medical University of Vienna (Austria)
  • Residencies: Medical University of Vienna (Austria); Memorial Sloan Kettering Cancer Center
  • Fellowships: Memorial Sloan Kettering Cancer Center
  • Board Certifications: Nuclear Medicine


Visit PubMed for a full listing of Christopher Riedl’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.

Learn more Arrow rightAn icon showing an arrow pointing to the right.


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicare and New York State Medicaid also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.